JNNP Podcast Podcast Por BMJ Group arte de portada

JNNP Podcast

JNNP Podcast

De: BMJ Group
Escúchala gratis

The Journal of Neurology, Neuroscience and Psychiatry (JNNP) Podcast is proud to reflect JNNP’s ambition to publish the most ground-breaking and cutting-edge research from around the world - jnnp.bmj.com. Encompassing the entire genre of neurological sciences, our focus is on the common disorders (stroke, multiple sclerosis, Parkinson’s disease, epilepsy, peripheral neuropathy, subarachnoid haemorrhage and neuropsychiatry), but with a keen interest in the Gordian knots that present themselves in the field, such as ALS. Join Dr. Saima Chaudhry as she hosts in-depth interviews with authors, providing a deeper understanding of their work and shedding new light on their findings. Stay informed with expert discussions and cutting-edge information by subscribing or listening on your favourite podcast platform.Copyright 2023 All rights reserved. Enfermedades Físicas Higiene y Vida Saludable
Episodios
  • Vestibular neurology for the generalist
    Jun 16 2025

    This episode guides the general neurologist through diagnosing and treating dizziness, vertigo, and balance disorders.

    Podcast editor and host, Dr Saima Chaudhry, interviews Dr Diego Kaski about his review titled, Vestibular neurology for the generalist. They cover common vestibular conditions, standard assessments, and new advances in genotyping and treatments, allowing a more accessible vestibular neurology.

    Dr Saima Chaudhry is an assistant professor of neurology at the Warren Alpert Medical School, Brown University, Rhode Island, USA. Dr Diego Kaski is a consultant neurologist at the National Hospital for Neurology and Neurosurgery, honorary associate professor at University College London, UK.

    Please subscribe to the show on Apple Podcasts, Spotify or find it on your platform of choice. Your feedback and reviews are very appreciated.

    Follow JNNP on twitter: @JNNP_BMJ

    Más Menos
    46 m
  • Cyclophosphamide for myasthenia gravis: a comeback?
    Apr 17 2025

    Patients with refractory or high-risk myasthenia gravis (MG) respond poorly to conventional immunosuppressive therapy, requiring rescue therapies and often experiencing treatment toxicity. The study discussed in this podcast suggests that lower doses of cyclophosphamide can be effective and safe in people with MG, including older age. JNNP's podcast editor, Saima Chaudhry, is joined by Professor Carolina Barnett-Tapia, University of Toronto, University Health Network, who authors the editorial comment 'Cyclophosphamide for myasthenia gravis: a comeback?'(https://jnnp.bmj.com/content/95/12/1095). The original paper is also free to access: https://jnnp.bmj.com/content/95/12/1096.

    Please subscribe to the show on Apple Podcasts, Spotify or find it on your platform of choice. Your feedback and reviews are very appreciated.

    Follow JNNP on twitter: @JNNP_BMJ

    Más Menos
    38 m
  • Management methods for acute ischaemic stroke
    Feb 13 2025

    The effectiveness of endovascular treatment (EVT) in cases of acute ischaemic stroke caused by distal medium vessel occlusion (DMVO) is still unclear. A study in the JNNP assessed the safety and effectiveness of EVT in comparison to the best medical management for DMVO. Podcast host Dr. Saima Chaudhry¹ spoke to some of the paper's authors, Dr. Adam Dmytriw², Dr. Vivek Yedavalli³ and Dr. Hamza Salim³.

    Read the paper: Endovascular therapy versus best medical management in distal medium middle cerebral artery acute ischaemic stroke: a multinational multicentre propensity score-matched study

    1. Warren Alpert Medical School, Brown University, Rhode Island, USA

    2. Neuroendovascular Program, Massachusetts General Hospital, Boston, Massachusetts, USA

    3. Radiology, Johns Hopkins Medicine, Baltimore, Maryland, USA

    Please subscribe to the show on Apple Podcasts, Spotify or find it on your platform of choice. Your feedback and reviews are very appreciated.

    Follow JNNP on twitter: @JNNP_BMJ

    Más Menos
    27 m
Todavía no hay opiniones